Jingzhi Cikang: Inheritance and Innovation of Pure Chinese Medicine
Release time:
2020-12-22
Jingzhi Cikang: Inheritance and Innovation of Pure Chinese Medicine Top-grade
Health Care Function of Jingzhi Cikang, which is to enhance immunity, mainly inherits the theory of traditional Chinese medicine. It combines 6 medicinal materials (including 4 top-grade Chinese medicines, 1 Chinese medicine and 1 medicinal guide) according to the principles of king, minister, assistant and make.
Compendium of Materia Medica holds that "Rhodiola rosea, dispelling evil spirits and making up for deficiencies" is "rare in known tonics". Ancient books such as "Shen Nong's Materia Medica" and "Compendium of Materia Medica" also record that Ganoderma lucidum is beneficial to the heart, enters the heart and generates blood, helps the heart and pulse, calms the nerves, invigorates the lungs, invigorates the essence, strengthens the muscles and bones, and so on. Astragalus main tonic qi, known as the "king of qi", is often used in body decay for a long time, low speech, pulse weakness. Ginseng is the main tonic and is known as the "king of traditional Chinese medicine". Zhang Zhongjing's "Treatise on Febrile Diseases" discusses that ginseng has the functions of warming, nourishing, strengthening, strengthening essence, heat preservation, enhancing eyesight, and stabilizing spirit. Acanthopanax senticosus is a tonifying medicine, which has the effects of tonifying the middle, invigorating essence, strengthening muscles and bones, and strengthening the will. "Shen Nong's Materia Medica" records cinnamon "tastes and produces temperature, dominates all kinds of diseases, nourishes spirit, and color, benefits joints, invigorates the middle and invigorates qi, hires all kinds of medicines first, takes long time to pass the spirit, lightens the body and never grows old". Cinnamon has the functions of replenishing fire and helping yang, igniting fire and returning to the source, dispelling cold and relieving pain, and promoting blood and promoting blood and passing. The main features and advantages of
Jingzhi Cikang are also reflected in the innovative application of modern technology. It uses low-temperature wall-breaking technology to fully break the wall of extremely fine (only a few microns) hard and insoluble spore powder cells, and uses modern extraction technologies such as supercritical fluid extraction to enrich various functional components in the formula, thus making a safe, effective, convenient, beautiful and highly bioavailable soft capsule preparation, it can play the role of multi-component, multi-channel and multi-target to enhance immunity, so as to enhance the nutritional and health effects of this product on the human body. (Yang Hao)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page